Exabis Library
Welcome to the e-CCO Library!
P430 Feasibility and reliability of gastrointestinal ultrasound in pregnant inflammatory bowel disease patients
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P430: Distinct faecal bile acid profiles are associated with sustained remission following exclusive enteral nutrition (EEN) induction therapy in paediatric Crohn's disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P430: EirSwitch echoes of NorSwitch: switching biosimilar therapy in an IBD cohort an Irish experience
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P430: European clinician perspective on withdrawing immunosuppression
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P430: Longer-term tofacitinib effectiveness for the treatment of ulcerative colitis: Two-year outcomes from a UK observational cohort study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P430: Mesalazine dose modification based on fecal calprotectin levels in ulcerative colitis patients in clinical remission
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P430: Prognostic significance of neuropeptide expression in ileal neural plexuses in Crohn’s disease. A retrospective study.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P430: Prognostic significance of serial faecal calprotectin in inflammatory bowel disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P431 Vitamin D binding protein in the limelight: IBD-related inflammation and circulating levels of vitamin D binding protein, total, free and bioavailable 25-hydroxyvitamin D
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P431: A Pan-European Real-World Study of SB5 biosimilar following transition from reference adalimumab: The PROPER study; 48-week analysis of persistence
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P431: Colonic Treg levels are reduced in patients with ulcerative colitis achieving clinical remission, but are not differentially affected by etrolizumab dose
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P431: Early mucosal healing at week 10 with ozanimod predicts clinical outcomes at week 52: Post hoc analysis of the phase 3 True North clinical trial
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P431: Golimumab dried blood spot analysis (GOUDA): A prospective trial to validate golimumab concentration analysis using the dried blood spot methodology
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P431: Teduglutide use and nutritional outcomes in short bowel syndrome with intestinal failure: a real-world claims database analysis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P431: Transabdominal ultrasonography to assess intestinal wall thickness and vascularity appears to predict therapeutic effects of steroid treatment in moderate-to-severe ulcerative colitis patients
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P431: Validation of a therapeutic drug monitoring test to measure the adalimumab biosimilar SB5 in comparison with the reference adalimumab
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P432 Effects and safety of a colon-long absorbing budesonide product in patients with mild to moderate ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P432: Barriers to prescribing anti-TNF therapy in inflammatory bowel disease (IBD) across newly industrialised emerging market countries: an analysis of the ‘EXPLORE’ study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P432: Does medical acceleration improve long-term outcomes in ulcerative colitis patients who are in clinical remission but have endoscopic mucosal inflammation?
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P432: MyChart application in addressing Inflammatory Bowel Disease patients’ concerns and impact on service utilisation
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM